Dermatomyositis skin signs

01OverviewDefinition, clinical context and the essential points that orientate the chapter.

Dermatomyositis is an immune-mediated microvascular and interface disease of skin, skeletal muscle and sometimes lung, swallowing, heart and other organs. Skin can precede weakness, occur with active myositis or persist in clinically amyopathic disease. Gottron lesions and heliotrope change are the most recognisable clues, but scalp scale, poikiloderma, nailfold capillary loss, mechanic hands and cutaneous ulceration may provide the first route to diagnosis.

Visible colour varies across pigmentation. Erythema may be red, violaceous, grey-brown or predominantly hyperpigmented; oedema, scale, telangiectasia, dyspigmentation and distribution should be recorded explicitly. Pruritic scalp disease can be mistaken for psoriasis or seborrhoeic dermatitis, while Gottron papules may be overlooked as dark knuckle change. Palpating scale and examining cuticles with magnification reduces inequitable under-recognition.

Skin phenotype predicts extracutaneous risk imperfectly. Anti-MDA5 disease can have little muscle enzyme elevation yet severe ILD. Anti-TIF1-gamma and several clinical variables shape malignancy assessment in adult onset. Treatment therefore starts with organ mapping, not a topical prescription alone. Photoprotection and local therapy relieve limited skin disease; objective weakness, dysphagia, lung disease, ulceration or persistent severe skin activity requires rheumatology–dermatology systemic treatment and rehabilitation.

Key points

Gottron papules are violaceous or erythematous papules over knuckles; Gottron sign is flat change over extensor joints. Heliotrope eyelid colour and oedema are also characteristic.
Photosensitive shawl, V-neck and lateral-thigh holster eruptions, scalp inflammation, ragged cuticles and abnormal nailfold capillaries add a coherent skin phenotype.
In brown or black skin, inflammation may look purple-brown, grey or hyperpigmented and scale or oedema may be more visible than red colour.
Ask about stairs, rising from a chair, lifting arms, hair washing, swallowing, voice, cough and breathlessness and test objective proximal power rather than equating pain or fatigue with weakness.
Normal creatine kinase does not exclude dermatomyositis, clinically amyopathic disease or interstitial lung disease; use aldolase, other muscle enzymes, antibodies, MRI, EMG and tissue according to phenotype.
Anti-MDA5 with ulceration or palmar papules increases concern for rapidly progressive ILD, while anti-TIF1-gamma in adult-onset disease heightens malignancy vigilance.
Complete routine national cancer screening and add symptom-, age-, sex- and antibody-informed investigation near adult disease onset rather than applying one scan to everyone forever.
First-line skin care combines high-UVA photoprotection with a site-appropriate topical corticosteroid or calcineurin inhibitor; persistent or scarring disease needs systemic control.
Methotrexate, hydroxychloroquine, mycophenolate and other steroid-sparing medicines are selected by muscle, skin, lung and reproductive phenotype; methotrexate is once weekly, never daily.

02AetiologyUnderlying causes, associations and risk factors, with why each one matters.

Autoimmune microvascular disease

Complement, interferon and cellular immune pathways injure skin and muscle microvasculature in a genetically susceptible person.

Antibody-defined phenotypes

Myositis-specific antibodies correlate with differing skin, lung, muscle and malignancy risks but do not create disease without a compatible phenotype.

Cancer-associated immune response

In some adults an antitumour immune response cross-reacts with regenerating tissue, linking disease onset to an occult or recent malignancy.

Ultraviolet amplification

Ultraviolet light exposure aggravates epidermal interface inflammation and shapes the shawl, V-neck and other characteristic photodistributed cutaneous patterns.

03PathophysiologyThe causal sequence from the underlying abnormality to symptoms and harm.

1
Interface skin injury
Immune attack at basal epidermis produces scale, pigment alteration, telangiectasia and atrophy across characteristic extensor and light-exposed sites.
2
Capillaries are damaged
Systemic microangiopathy creates giant nailfold loops, visible haemorrhage and progressive capillary loss and also contributes to perifascicular muscle injury.
3
Muscle fibres lose power
Inflammation and ischaemic signalling injure proximal muscle, reducing force for rising, climbing, lifting, swallowing and breathing.
4
Lung inflammation may dominate
Selected phenotypes, especially anti-MDA5 disease, drive aggressive interstitial lung injury even when muscle enzymes and strength remain near normal.

04Clinical features and red flagsSymptoms, examination findings, patterns of presentation and time-critical warnings.

Gottron papules

Flat-topped scaly violaceous, red-brown or hyperpigmented papules lie over metacarpophalangeal and interphalangeal joints and may fissure.

Heliotrope change

Upper eyelids show violaceous, dusky or grey-brown colour with oedema, sometimes more evident as swelling than erythema.

Photodistributed poikiloderma

Shawl, V-neck and lateral-thigh areas develop mixed pigment, telangiectasia, scale and atrophy with photosensitive worsening.

Nailfold microangiopathy

Ragged cuticles, periungual erythema, giant loops, haemorrhage and capillary loss support systemic microvascular involvement.

Mechanic hands

Hyperkeratotic fissured radial fingers and palms can signal antisynthetase overlap, especially with arthritis, Raynaud phenomenon or lung disease.

Ulcerative MDA5 patternRed flag

Painful ulcers over Gottron sites or nailfolds and palmar papules raise rapidly progressive ILD concern even without weakness.

Objective proximal weakness

Difficulty rising, climbing, lifting or holding the neck reflects symmetrical shoulder and hip-girdle weakness and requires organ-level myositis assessment.

Red flags requiring action

Skin ulceration, palmar papules, anti-MDA5 phenotype, new dyspnoea, dysphagia, objective proximal weakness, myocarditis symptoms, constitutional decline or malignancy warning features requires expedited multidisciplinary assessment even when creatine kinase is normal.

05InvestigationsWhat to request, why it matters and how to interpret it.

Investigation order

Read from the initial assessment onwards. Tests may run in parallel in urgent care; first-line, preferred, confirmatory, definitive and gold-standard labels appear only when the chapter explicitly states them.

01
Functional and manual muscle assessmentFirst step
Why
Prove weakness, map distribution and establish an outcome baseline.
Interpretation and limitations
Symmetrical proximal weakness supports inflammatory myopathy; preserve distinction from pain, fatigue, neuropathy, steroid myopathy and inclusion-body patterns.
02
CK, aldolase, AST, ALT, LDH and urine
Why
Detect muscle injury and renal risk and create a treatment-response baseline.
Interpretation and limitations
Normal CK does not exclude active skin disease, amyopathic dermatomyositis or ILD; AST and ALT can be muscular, while myoglobinuria and AKI are urgent.
03
Myositis-specific antibody panel
Why
Refine skin, lung, malignancy and treatment-risk phenotype.
Interpretation and limitations
Anti-MDA5, TIF1-gamma, NXP2 and antisynthetase results inform vigilance but line-blot false positives occur and antibodies never replace the clinical syndrome.
04
Skin biopsy
Why
Support interface disease and exclude mimics when characteristic morphology is incomplete.
Interpretation and limitations
Basal vacuolar injury, mucin and lymphocytes overlap with cutaneous lupus, so site, photographs, weakness and serology determine clinicopathological meaning.
05
Muscle MRI, EMG and biopsy
Why
Confirm and subtype muscle involvement when enzymes and examination do not provide enough certainty.
Interpretation and limitations
MRI guides biopsy to active non-end-stage muscle; exercise and denervation can mimic oedema and treatment can lower histological yield.
06
Swallow and respiratory assessment
Why
Detect aspiration, ventilatory weakness and myositis-associated ILD before catastrophic deterioration.
Interpretation and limitations
Use speech-and-language evaluation, FEES or videofluoroscopy, seated and supine FVC, gas transfer and HRCT according to symptoms and antibody risk.
07
Risk-stratified malignancy assessment
Why
Identify cancer associated with adult-onset dermatomyositis near presentation.
Interpretation and limitations
Complete national screening and add history-, examination-, age-, sex- and antibody-directed imaging or endoscopy; repeat investigation follows evolving risk rather than one universal schedule.

06Differential diagnosisRealistic alternatives and the features that help distinguish them.

Cutaneous lupus

Photosensitive interface disease can overlap, but Gottron lesions, muscle weakness, nailfold changes and myositis antibodies favour dermatomyositis.

Psoriasis or eczema

Scaly scalp and knuckle disease may mimic common dermatitis, but eyelid oedema, poikiloderma and systemic features require broader assessment.

Systemic sclerosis

Raynaud phenomenon and capillary loss overlap, while sclerodactyly, fingertip ulcers and progressive skin thickening define a different connective-tissue pattern.

Drug or endocrine myopathy

Statin injury, glucocorticoid weakness, thyroid disease and other toxic or metabolic causes lack the coherent characteristic cutaneous signs.

Inclusion-body myositis

Slow asymmetric finger-flexor and knee-extensor weakness in later life, often with modest enzymes, responds poorly to ordinary immune treatment.

07ManagementImmediate care, first-line treatment, alternatives and escalation.

01First diagnostic sequenceUse skin to trigger whole-organ mappingFirst stepGottron, heliotrope, photodistributed or nailfold features suggest dermatomyositis.

1Photograph skin in neutral light with consent and examine scalp, eyelids, knuckles, nails, hands and thighs, then measure proximal, neck and respiratory function and ask about swallow.
2Request muscle enzymes, renal and urine tests and phenotype-directed antibodies, adding skin biopsy, muscle MRI, EMG or muscle biopsy when the diagnosis remains uncertain.
3Screen lungs, swallowing, heart and malignancy from symptoms, disease onset and antibody risk and refer urgently for ulcerative MDA5 features or physiological compromise.

02First-line skin treatmentProtect from light and suppress local activityFirst lineCutaneous disease is limited and no organ-threatening feature requires immediate systemic rescue.

1Use high-UVA broad-spectrum sunscreen, shade and protective clothing and review photosensitising products while protecting vitamin D and quality of life.
2Apply a site-appropriate topical corticosteroid to active trunk, scalp or limb disease and use an off-label calcineurin inhibitor where face or folds make steroid atrophy unacceptable.
3EscalationReview itch, scale, ulceration, poikiloderma and functional hand disease within weeks and escalate persistent or scarring activity rather than renewing topical treatment indefinitely.

03Systemic and rehabilitation careMatch steroid-sparing treatment to organsObjective weakness, dysphagia, lung disease or extensive resistant skin requires systemic immune treatment.

1Use specialist glucocorticoid for active muscle disease and introduce methotrexate, mycophenolate, azathioprine or another organ-matched steroid-sparing medicine early.
2For skin-predominant disease consider hydroxychloroquine with actual-weight retinal safeguards, recognising variable efficacy and the possibility of a drug eruption.
3Begin physiotherapist-led progressive exercise and occupational support during immune treatment rather than prescribing prolonged rest that worsens deconditioning.

04Organ or cancer escalationProtect lung, swallow and diagnostic windowEscalationMDA5 skin features, dyspnoea, dysphagia, myocarditis symptoms or adult malignancy risk is present.

1Admit deteriorating respiratory or bulbar disease for gas exchange, supine and seated respiratory testing, swallow imaging and early feeding or ventilatory support.
2Coordinate rapid multidrug immune treatment for progressive ILD and avoid waiting for CK elevation when the skin and lung phenotype is compelling.
3Complete risk-adapted malignancy investigation and revisit new symptoms during follow-up, keeping cancer treatment and myositis control coordinated across specialties.

Key medicines and prescribing safety3 treatments · regimens, roles and cautions

Controls local itch and interface inflammation as part of first-line treatment for limited cutaneous dermatomyositis.

Site-appropriate topical corticosteroid

Apply a thin layer once daily to active nonfacial skin or scalp for a defined two-to-four-week course, then review before reducing or continuing intermittently.

Use lower potency on eyelids, face and folds and monitor atrophy, telangiectasia, infection and total area; topical control cannot replace lung, muscle, swallow and malignancy assessment.

A steroid-sparing antimalarial option for persistent photosensitive cutaneous disease when the systemic phenotype permits it.

Hydroxychloroquine for skin-predominant disease

Take 200–400 mg by mouth once daily with food without exceeding 5 mg/kg actual body weight daily, under specialist response and retinal review.

Response is variable and dermatomyositis patients can develop drug eruptions. Review retinal, renal, cardiac, QT, glucose and interaction risk and stop and reassess a new widespread rash.

Steroid-sparing systemic treatment for persistent skin and muscle inflammation when lung and reproductive context makes it suitable.

Methotrexate with folic acid

Start 7.5–15 mg by mouth or subcutaneous injection once weekly with folic acid at least 5 mg on a different day, titrating only through specialist monitoring.

Never administer daily. Monitor FBC, liver and renal function; avoid pregnancy, significant liver disease, serious infection and trimethoprim or co-trimoxazole, and investigate new cough or breathlessness urgently.

08ComplicationsImportant consequences, why they occur and why they matter clinically.

Aspiration and respiratory failure

Bulbar and respiratory-muscle weakness causes unsafe swallowing, aspiration pneumonia, weak cough, nocturnal hypoventilation and ventilatory collapse.

Interstitial lung disease

Inflammatory and fibrotic lung injury ranges from indolent restriction to rapidly progressive hypoxic failure, particularly in anti-MDA5 disease.

Associated malignancy

Adult-onset disease can signal cancer near diagnosis, with risk modified by age, symptoms, phenotype and antibodies.

Calcinosis and fixed damage

Chronic inflammation can leave calcium deposits, ulceration, contracture, poikiloderma and muscle fatty replacement despite later immune control.

Treatment toxicity

Glucocorticoid and steroid-sparing therapy causes infection, metabolic, bone, blood, liver, lung and reproductive harms requiring structured surveillance.

09Monitoring and follow-upTreatment response, safety checks and longer-term review.

Record Gottron, scalp, nailfold, ulcer and poikiloderma activity separately from fixed atrophy, calcinosis and pigment using reproducible photographs.
Measure functional strength, swallow, cough and respiratory symptoms at every systemic review even when the patient presents primarily for skin.
Trend CK and other enzymes beside function; biochemical improvement with persisting weakness can reflect damage, steroid myopathy or inadequate rehabilitation.
For anti-MDA5 or respiratory risk, follow FVC, DLCO, oxygenation and HRCT through the specialist protocol and escalate any accelerating decline.
Maintain age- and risk-adapted cancer screening and investigate new weight loss, bleeding, mass or focal symptoms promptly.
Apply medicine-specific blood, liver, renal, infection, retinal, bone, vaccination and reproductive monitoring and verify weekly methotrexate dosing.

10Special situationsVariants, exceptions and circumstances that change the usual approach.

Skin can precede muscle

Characteristic lesions may appear months before weakness, creating an opportunity for lung, swallow and cancer assessment before other organs declare themselves.

CK is not a lung screen

Amyopathic anti-MDA5 disease can have normal enzymes yet life-threatening interstitial lung progression, so phenotype and respiratory testing outrank reassurance.

Knuckle colour is not callus

Gottron papules can appear dark brown or grey with fine scale in richly pigmented skin and deserve palpation, nailfold examination and systemic history.

Biopsy cannot separate every interface disease

Cutaneous lupus and dermatomyositis overlap histologically, making distribution, muscle, nailfold and antibody context indispensable.

Weakness and fatigue differ

Objective loss of proximal power is measured during tasks and examination; severe fatigue can coexist but should not substitute for strength assessment.

11Common pitfallsFrequent interpretation and management errors.

01
Dismissing dark scaly knuckles as friction without checking Gottron morphology and nailfolds.
02
Using a normal CK to exclude dermatomyositis or MDA5-associated lung disease.
03
Treating scalp and facial disease topically while failing to ask about swallowing and breathlessness.
04
Interpreting one commercial myositis antibody line as diagnostic without a compatible phenotype.
05
Giving methotrexate daily instead of weekly or omitting blood, liver, renal and pregnancy safeguards.
06
Applying a single lifelong whole-body cancer scan schedule rather than risk- and symptom-adapted assessment.